FDA Grants Priority Review to Roche's Lung Cancer Drug Tecentriq
Roche (OTC: RHHBY) announced on Wednesday that the U.S. Food and Drug Administration had accepted its supplemental Biologics License Application for the cancer drug Tecentriq. In addition, the FDA also granted a Priority Review to the drug for use in patients with non-squamous and squamous non-small cell lung cancers.
This approval was based on recent clinical results from the phase 3 IMpower110 study, which evaluated Tecentriq as a monotherapy in comparison to other types of chemotherapy. The results showed that Roche's cancer drug improved overall survival time by 7.1 months. The FDA is expected to review the data and come to a decision by June 19.
Image source: Getty Images.
Source Fool.com
